Wednesday, 26 August 2026

Health Alert: FDA approves pancreatic cancer drug that in trials extended patients’ lives

Revolution Medicines’ drug, known as Rasonque or daraxonrasib, nearly doubled patients’ average survival times in treating one of the deadliest cancers, the agency said. The Food and Drug Administration had expanded access for daraxonrasib in May as it underwent review, stating that the drug met a critical need in treating pancreatic cancer.

El-Sayed clashes with Jesse Watters over ‘transgender’ procedures, ICE, Sharia law in tense interview